AUTHORS

Real Money authors - Bruce Kamich

Bruce Kamich

Bruce Kamich is TheStreet's in-house technical analyst with a 43 year career with a number of bulge bracket firms like Morgan Stanley, Smith Barney Harris Upham, and Merrill Lynch. Along the way he accumulated knowledge about the fundamentals of the commodity markets, interest rates, equities and ETFs. 

In addition to writing for theStreet.com Kamich has been teaching technical analysis at Baruch College for the past twenty years.

Kamich was one of the earliest Chartered Market Technicians  or CMTs, a professional designation similar to the CFA title. He has authored two books on charting and technical analysis - "How Technical Analysis Works"  and "Chart Patterns." He is a two-time past president of the Market Technicians Association (now called the CMTA), the professional organization for chartists worldwide. He was also the president of the Market Technicians Association Educational Foundation (MTAEF.org).
Email Bruce Kamich

Recent Articles By The Author

Honeywell Spinoffs Are Not Attracting Strong, Committed Buyers

Let's check out a couple of charts of Garrett Motion and Resideo Technologies.

Twilio Investors Are Voting With Their Feet

This cloud stock could weaken further in the weeks ahead

Weak Sales Plague Ford Motor

Will the charts indicate if there are better times ahead?

Dow Inc Is Poised to Rally After Making a Three-Month Base

Let's check out a couple of charts of DOW.

Intel Is Breaking Out on the Upside, Buy or Add to Longs

Let's look closely at the charts and indicators.

Lam Research Should Continue Its Uptrend to New Heights

Let's review the charts and indicators.

Amazon Is Set to Gap Lower Friday: Here's Our Strategy

Let's check the charts and indicators for some guidance.

American Electric Power Could Power Its Way Higher

Let's check out the charts of AEP to see if the rally is renewable.

Centene Is Finally Showing Some Bullish Divergences

It is early in the game but here's what traders can do.

Abbott Labs Has Concocted a Way to Advance Further

The medical device and health care company is set to resume its long advance, with our first price target at $92 and next at $100.

Email sent

Thank you, your email to has been sent successfully.

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight